Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
Triple combination of inhibitors emerges as potential new treatment for aggressive cancer
A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
Precigen's SWOT analysis: biotech firm's stock poised for growth with PRGN-2012
Precigen, Inc. (NASDAQ:PGEN), a biotechnology company specializing in gene and cell therapies with a market capitalization of $398.3 million, is on the cusp of a significant transformation as it ...
The American Journal of Managed Care6d
Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care
Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...